AGLE | Aeglea BioTherapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	10.69 - 12.34
52 Week Range	2.6600 - 24.00
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	43,238
Average Volume	59,537
Shares Outstanding	4,048,930
Market Cap	48,627,649
Sector	Healthcare
Industry	Biotechnology
IPO Date	2016-04-07

Valuation
Profitability
Growth
Health
P/E Ratio	-0.16
Forward P/E Ratio	N/A
EPS	-74.15
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	69
Country	USA
Website	AGLE

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.

AGLE's peers: APTO, EPIX

*Chart delayed

Analyzing fundamentals for AGLE we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is very weak. For more detailed analysis please see AGLE Fundamentals page.

Watching at AGLE technicals we can see that long-term trend is bullish, while middle-term trend is bearish, as well as bearish short-term trend. More technicals details can be found on AGLE Technicals page.